EMA Approves Ocular Formulation of Bevacizumab EMA Approves Ocular Formulation of Bevacizumab
Europe has approved the use of monoclonal antibody bevacizumab for the treatment of neovascular age-related macular degeneration.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 22, 2024 Category: Drugs & Pharmacology Tags: Ophthalmology Source Type: news
Lonsurf/Bevacizumab for Advanced Metastatic Colorectal Cancer Lonsurf/Bevacizumab for Advanced Metastatic Colorectal Cancer
Dr David J. Kerr discusses the approval of the combination of Lonsurf (trifluridine-tipiracil) and bevacizumab in the third-line treatment of advanced metastatic colorectal cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2024 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC
A new study showed improved progression-free survival when systemic therapy is added to TACE for HCC. Overall survival outcomes are pending.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news
Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer
MONDAY, Jan. 29, 2024 -- For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) improves progression-free survival (PFS),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 29, 2024 Category: Pharmaceuticals Source Type: news
Atezolizumab Plus Standard Care Improves Survival in Advanced Cervical Cancer
FRIDAY, Jan. 5, 2024 -- For patients with metastatic, persistent, or recurrent cervical cancer, adding atezolizumab to a standard bevacizumab plus platinum regimen significantly improves progression-free and overall survival, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 5, 2024 Category: Pharmaceuticals Source Type: news
FDA Approves Avzivi (bevacizumab-tnjn), a Biosimilar to Avastin
GUANGZHOU, China, Dec. 7, 2023 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets, today announced that the United States Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 7, 2023 Category: Drugs & Pharmacology Source Type: news
Adding Atezolizumab Improves Survival in Advanced Cervical Cancer
(MedPage Today) -- First-line treatment with the anti-PD-L1 inhibitor atezolizumab (Tecentriq) combined with bevacizumab (Avastin) and platinum-based chemotherapy significantly improved survival in patients with metastatic or recurrent cervical... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 3, 2023 Category: Hematology Source Type: news
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, …
(Source: Reuters: Health)
Source: Reuters: Health - October 21, 2023 Category: Consumer Health News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecen...
Source: Roche Media News - October 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
No Benefit to Extending Bevacizumab in Ovarian Cancer No Benefit to Extending Bevacizumab in Ovarian Cancer
Maurie Markman, MD, discusses results from a pragmatic clinical trial regarding extended frontline treatment with bevacizumab in patients with ovarian cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 16, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
FDA Approves Lonsurf (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC)
Approval clinical trial showing that treatment with Lonsurf plus bevacizumab resulted in statistically significant and clinically meaningful improvements in overall survival in patients with previously treated mCRC compared to Lonsurf as a single... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 2, 2023 Category: Drugs & Pharmacology Source Type: news
FDA OKs Trifluridine/Tipiracil Plus Bevacizumab for mCRC FDA OKs Trifluridine/Tipiracil Plus Bevacizumab for mCRC
Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 2, 2023 Category: Gastroenterology Tags: Hematology-Oncology News Alert Source Type: news
